Raw and adjusted prevalence ratios of HR-HPV genotypes different from 16/18/31/33/45, in vaccinated <i>vs</i>. unvaccinated women, unvaccinated women <i>vs</i>. pre-vaccination period, vaccinated women <i>vs</i>. pre-vaccination period, and post-vaccination period (vaccinated and unvaccinated women) <i>vs</i>. pre-vaccination period.

<p>Raw and adjusted prevalence ratios of HR-HPV genotypes different from 16/18/31/33/45, in vaccinated <i>vs</i>. unvaccinated women, unvaccinated women <i>vs</i>. pre-vaccination period, vaccinated women <i>vs</i>. pre-vaccination period, and post-vaccination period (vaccinated and unvaccinated women) <i>vs</i>. pre-vaccination period.</p

Characteristics of women in the pre-vaccination (2008–10) and post-vaccination period (2014–17).

<p>Characteristics of women in the pre-vaccination (2008–10) and post-vaccination period (2014–17).</p

Post-vaccination period (2014–17): Characteristics of unvaccinated and vaccinated women.

<p>Post-vaccination period (2014–17): Characteristics of unvaccinated and vaccinated women.</p

HPV 16/18: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

<p>HPV 16/18: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.</p

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

<p>HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.</p

Global HR-HPV group prevalence by period of study.

<p><b>HR-HPV group prevalence in post-vaccination period by vaccination status and post-vaccination biennium</b>.</p

Adjusted effectiveness of HR-HPV 16/18 and 31/33/45, in vaccinated <i>vs</i>. unvaccinated women in the post-vaccination period (direct effectiveness), unvaccinated women in the post-vaccination period <i>vs</i>. women in the pre-vaccination period (indirect effectiveness), vaccinated women <i>vs</i>. women in the pre-vaccination period (total effectiveness), and vaccinated and unvaccinated women in the post-vaccination period <i>vs</i>. women in the pre-vaccination period (overall effectiveness).

<p>Adjusted effectiveness of HR-HPV 16/18 and 31/33/45, in vaccinated <i>vs</i>. unvaccinated women in the post-vaccination period (direct effectiveness), unvaccinated women in the post-vaccination period <i>vs</i>. women in the pre-vaccination period (indirect effectiveness), vaccinated women <i>vs</i>. women in the pre-vaccination period (total effectiveness), and vaccinated and unvaccinated women in the post-vaccination period <i>vs</i>. women in the pre-vaccination period (overall effectiveness).</p

Recommendation starting points: Organizations and institutions—Top-down.

Recommendation starting points: Organizations and institutions—Top-down.</p

Full list of 14 recommendations.

A list of all recommendations developed and accepted by the authoring group. (DOCX)</p

The Bicycle Principles.

“The Principles” represent a framework for recommendations to improve SFT. One cycle comprises "Core Principles" that all SFT should meet, that is, SFT should be: (based on) Best Evidence, Effective, Inclusive, Catalytic. The second cycle of “Community Principles” apply when the SFT is developed with the potential or intention to be reused and disseminated beyond the original or initial deployment, that is, it should promote: Reach, Scale, and Sustain. These two iterative cycles make up the “bicycle”.</p